17 
said t±iat rnany DOD biomedical research projects are unclassified, but there 
are projects in defensive biological warfare techniques and processes that 
are classified. These projects might include aerosol detection devices, 
antibody identification devices, or air sampling processes. These are 
not weapons. 
Dr. Goldstein asked if the motion made earlier in the meeting concerning the 
use of recombinant EflSIA technology for biological warfare might be recon- 
sidered. Dr. Ahmed seconded. By a vote of five in favor, thirteen opposed, 
and no abstentions the RAC refused to reconsider the earlier motion. 
Mr. Thornton called the attention of the RAC to Part D of tab 1072 which 
includes certain sections of the current Guidelines which the working group 
suggested deleting but which NIH staff felt should be retained. He said 
the version which Er. Ahmed had moved includes these sections. If any 
member does not approve of the retention of any section, a specific motion 
to delete should be made. The sections to be retained are; (1) Section 
I-D-5 of Section I-D, General Definitions , which defines "Director, NIH," 
(2) Section IV-B-5-b and its subsections of IV-B-5, Principal Investigator , 
which deals with submissions by the principal investigator to the NIH, (3) 
Section IV-C-l-b-(l)-(a) and Section IV-C-l-b-(l)-(b) of Section IV-C-1-^, 
Specific Responsibilities of the Director , and (4) Section IV-C-l-b-{2) 
and its subsections which detail certain lesser actions which are the 
responsibility of the Director. No motion to delete any of these 
sections was made. 
Dr. Brill returned to the issi£ of the classification of Klebsiella as a 
Class 2 agent in /^pendix B. He suggested that the language in Appendix B 
which reads " Klebsiella - all species and all serotypes" be modified to 
read " Klebsiella - all strains known to originate from human and animal 
sources." Dr. Gottesman asked what an investigator would assume if he 
did not know the source of a strain. Dr. Brill replied that an investi- 
gator would assume that particular Klebsiella strain was a Class 1 agent. 
Dr. Gottesman pointed out that no new restrictions were being imposed on 
investigators working with Klebsiella by the proposed revised Guidelines. 
She questioned the appropriateness of modifying this language at this 
RAC meeting without data sufficient to formulate a reasonable motion. 
She felt a working group could examine the issue in greater detail. 
Dr. Ahmed agreed the issue should be referred to a working group; he 
felt insufficient information was available at the monent. Dr. McKinney 
said the Classification of Etiologic Agents states that "human etio logic 
agents" have been classified. Presumably, those strains of Klebsiella 
classified in proposed ^pendix B are only the human pathogens. Dr. Tolin 
pointed out that Klebsiella appears in Sublist A of ^pendix A and, there- 
fore, many experiments involving Klebsiella will be totally exempt from 
the Guidelines. 
[476] 
